SARS-CoV-2 Vaccination and Attenuation of Breakthrough Infection Severity: A Systematic Global Review and Meta-analysis.
Caifen Liu, George N Okoli, Ruohan Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined whether COVID-19 vaccination attenuates disease severity among people with breakthrough infections, using global observational studies reporting matched vaccine-effectiveness estimates. Across 184 estimate pairs from 37 studies, pooled relative vaccine effectiveness against hospitalization versus broadly defined symptomatic infection was 51% (95% CI: 39%, 60%); versus medically attended symptomatic infection, it was 19% (95% CI: 12%, 25%). Attenuation was lower among adults aged ≥60 years, showed no significant waning over time, and did not differ significantly by vaccine platform. Variant patterns varied with the symptomatic-infection definition.
Key findings
- Pooled relative vaccine effectiveness was 51% (95% CI: 39%, 60%) against hospitalization versus broadly defined symptomatic infection.
- Against medically attended symptomatic infection, pooled relative vaccine effectiveness was 19% (95% CI: 12%, 25%).
- Attenuation was lower in adults aged ≥60 years and showed no significant waning over time.
- No significant differences were observed between vaccine platforms; Omicron attenuation was weaker when broadly defined symptomatic infection was the comparator.
Why it matters
Protection against infection is incomplete, so the extent to which vaccination reduces progression to severe outcomes is clinically important. These pooled observational estimates support a severity-attenuation benefit among breakthrough cases, while highlighting that estimates depend on how symptomatic infection is defined and that attenuation was lower in older adults. This context can help interpret vaccine effectiveness beyond infection prevention alone.
What to keep in mind
The analysis pooled observational studies and reported substantial heterogeneity; the authors note potential selection bias and inconsistent findings in the underlying evidence.